^
    2ms
    The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. (PubMed, Future Oncol)
    Particularly, IGH-BCL2 and IGH-CCND1 fusions were concordant between plasma and tumor biopsies in FLs (91.1%) and MCLs (91.3%), respectively. Longitudinal data demonstrated that ctDNA clearance correlated with complete response but ctDNA increases preceded radiological relapses. ctDNA exhibited high concordance with tumor biopsy in detecting genetic aberrations and demonstrated potential as a promising noninvasive approach to disease surveillance in non-DLBCL NHLs.
    Journal • IO biomarker • Circulating tumor DNA
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1)
    |
    Hemasalus™
    12ms
    The Clinical Utility of Plasma Circulating Tumor DNA in the Diagnosis and Disease Surveillance in non-DLBCL non-Hodgkin’s Lymphomas (ACMG 2024)
    Plasma ctDNA demonstrated high concordance with tumor biopsy in detecting genetic aberrations for non-DLBCL NHLs and serves as a promising surrogate of tumor biopsy in monitoring treatment response and disease progression in non-DLBCL NHLs.
    Clinical • Tumor mutational burden • IO biomarker • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1)
    |
    EZH2 mutation
    |
    Hemasalus™
    over1year
    Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer (Canada Newswire)
    "Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval. These approvals signify that GeneseeqPrime™ and GeneseeqPrime™ HRD are suitable for solid tumor genomic profiling, while Hemasalus™ DNA/Hemarna™ RNA is cleared for hematological cancer genomic profiling."
    European regulatory
    |
    GeneseeqPrime™ • GeneseeqPrime™HRD • Hemarna™ • Hemasalus™